SCHEMBL6409555

SCHEMBL6409555

CN1CCN(C2CCCc3ccc(C(=O)NCc4ccc(F)cc4)cc32)CC1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.58
DRD3 P35462 2/20 0.58
HTR1A P08908 1/20 0.58
LMNA P02545 3/20 0.46
KMT2A Q03164 1/20 0.46
MTNR1B P49286 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
POLB P06746 1/20 0.44
DRD2 P14416 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NAMPT P43490 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6407639 0.90 HTR2C (0.49) HTR2CDRD3HTR1ALMNAKMT2A
SCHEMBL6407460 0.90 HTR2C (0.58) HTR2CDRD3HTR1AKMT2AMTNR1B
SCHEMBL6404451 0.90 HTR2C (0.53) HTR2CDRD3HTR1ALMNASMN1; SMN2
SCHEMBL6405785 0.90 HTR2C (0.49) HTR2CDRD3HTR1AKMT2AMTNR1B
SCHEMBL6409860 0.89 HTR2C (0.48) HTR2CDRD3HTR1ALMNAKMT2A
SCHEMBL6405838 0.89 MTNR1B (0.58) MTNR1BPOLBDRD2MAPTALDH1A1
SCHEMBL6406000 0.87 CXCR3 (0.51) HTR2CDRD3HTR1ALMNAKMT2A
SCHEMBL6406698 0.84 HTR2C (0.53) HTR2CDRD3HTR1ALMNAMTNR1B
SCHEMBL6407417 0.83 HRH4 (0.52) HTR2CDRD3HTR1AKMT2AGAA
SCHEMBL6405348 0.82 KMT2A (0.58) LMNAKMT2AMTNR1BDRD2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288304-A1 Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists PFIZER INC 2005-12-29 US claimed
WO-2020183011-A1 HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER INSTITUT CURIE (FR) 2020-09-17 WO disclosed
US-20050288304-A1 Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists PFIZER INC 2005-12-29 US disclosed
WO-2005113527-A1 TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS PFIZER PRODUCTS INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288304-A1 Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists HTR1A, HTR1B, HTR1D HTR2C 8/4885DRD3 33/4885HTR1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.